MilliporeSigma, the Life Science business branch of Merck KGaA (based in the US and Canada), has finalized a deal to buy Mirus Bio for USD 600 million.
Mirus Bio is known for its expertise in the development and commercialization of transfection re-agents, under the name TransIT-VirusGEN, which are instrumental in transferring genetic material into cells. This makes them essential in the creation of viral vectors, a crucial element in the design of cell and gene therapies.
This acquisition is intended to bolster Merck's capabilities in viral vector manufacturing for gene and cell therapies. With the added competency of Mirus Bio, Merck aims to provide comprehensive solutions for all phases of viral vector manufacturing, thereby supporting the progression of cell and gene therapies from preliminary stages to final commercial production.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.